University Hospital MĂŒnster Medical Clinic A -Â Germany
Author ProfileÂ
ORCIDÂ
đ Early academic pursuits
Dr. Evgenii Shumilov began his academic journey in kirovskaya gebiet, russland, where he completed his general secondary education in june 2006. driven by a passion for human biology and clinical care, he enrolled in the staatliche medizinische akademie in kirow in 2006. the following year, he transitioned to the esteemed st. petersburger staatliche medizinische universitÀt i.p. pawlow, where he pursued his degree in human medicine until 2012. during this formative period, he developed a growing interest in the biochemical pathways influencing addiction, which would later shape his doctoral research.
đ„ Professional endeavors
His professional career started immediately after his graduation with a clinical internship in internal medicine at the universitĂ€tsklinikum st. petersburg i.p. pawlow. dr. shumilov then completed a specialized clinical training in oncology at the renowned n.n. petrow institute for oncology. from 2015 to 2021, he continued his facharztausbildung (specialist training) in internal medicine, hematology, and oncology at the universitĂ€tsmedizin göttingen. since 2021, he has served in various capacities at the universitĂ€tsklinikum mĂŒnster, advancing to oberarzt (senior physician) in the day clinic of oncology by 2022. his role requires the coordination of clinical therapies, implementation of modern diagnostics, and integration of interdisciplinary care â akin to the precision and optimization seen in power electronics systems.
đŹ Contributions and research focus
Dr. Shumilov has made significant scientific contributions in the field of pharmacology and hemato-oncology. between 2012 and 2015, he pursued a doctoral program in pharmacology at the anichkow institute for experimental medicine, focusing on neuropharmacology and the role of orexin-1 receptors in addiction â a study that mirrors the regulatory mechanisms of feedback and control in power electronics. in 2018, he earned a second doctorate (dr. med.) from the university of bern, switzerland, with a dissertation exploring genetic mutations bridging Oncology and Hematology hematopoietic lineages and solid tumors in the age of high-throughput sequencing. his work has helped redefine diagnostic paradigms in clinical oncology.
đ Impact and influence
Dr. Shumilovâs cross-disciplinary expertise bridges clinical practice and molecular diagnostics. his innovative thinking, reflected in his dual doctoral research and international academic Oncology and Hematology exposure, positions him as a leader in precision medicine. like the transformative role of power electronics in renewable energy systems, his influence lies in optimizing diagnostic accuracy and tailoring therapies for oncology patients. he is actively mentoring junior clinicians, integrating translational research into routine care, and contributing to academic networks across europe and russia.
đ Academic citations and recognitions
He has received notable academic recognition, including a posterpreis at the dgho annual meeting in stuttgart (2017), and the prestigious dfg âclinician scientistâ funding from 2020 to 2021. his scientific contributions are frequently cited in studies on neuropharmacology and next-generation sequencing diagnostics. his work on orexin receptors and hematologic malignancies Oncology and Hematology continues to influence both pharmacologic models and clinical protocols.
đ± Legacy and future contributions
Dr. Shumilovâs legacy lies in his capacity to interweave basic science with clinical oncology. he is currently leading projects that integrate high-throughput genomic data with patient-specific therapy plans, aiming for breakthroughs in hematologic and solid tumor treatments. with a forward-looking perspective, he is exploring digital integration and ai-assisted diagnostics, similar to how power electronics revolutionize control in automated systems. his future vision includes strengthening international research collaborations and expanding educational programs for medical scientists.
Notable PublicationsÂ
-
Title: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Author(s): Evgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, Paolo Mazzeo, Rebecca Wurm-Kuczera, Vladan Vucinic, Udo Holtick, Hristo Boyadzhiev, Thomas Melchardt, Alexander Sebastian Hölscher, et al.
Journal: Blood Advances
-
Title: Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning
Author(s): Evgenii Shumilov, Lena Levien, Paolo Mazzeo, Wolfram Jung, Andreas Leha, Raphael Koch, Justin Hasenkamp, Gerald Wulf
Journal: Leukemia & Lymphoma
-
Title: Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
Author(s): Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp B. Staber, Paolo Mazzeo, Corinna Leng, et al.
Journal: Blood Advances
-
Title: Benefit of repeated COVIDâ19 vaccination for patients with Bâcell malignancies
Author(s): Ulrike Bacher, Evgenii Shumilov, Thomas Pabst
Journal: British Journal of Haematology
-
Title: Radiotherapy in Combination with Systemic Therapy for Multiple MyelomaâA Critical Toxicity Evaluation in the Modern Treatment Era
Author(s): Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich
Journal: Cancers